FITC-EGFR Recombinant Antibody

【No.】IAB006A 【Antibody name】 FITC-EGFR recombinant antibody
【Antibody subtype】human IgG1 【Use】FACS
【Packing specification】100μg/tube 【Mode of transport】-20°C transportation

The human EGFR protein is a transmembrane receptor, which can be used as a tyrosine kinase receptor to bind to homologous ligands, activate multiple signal levels and convert extracellular signals into appropriate cellular responses. Its cognate ligand such as epidermal growth factor ( of EGF ) and transforming growth factor sub-α (TGFα) binding cells to the extracellular domain leads to EGFR dimerization and autophosphorylation of tyrosine residues in the cytoplasmic domain of [1] . Studies have shown that the presence of many solid tumors EGFR high expression or abnormal expression, EGFR proliferation of tumor cells, angiogenesis, tumor invasion and metastasis, and inhibition of apoptosis-related [2,3] . Therefore , monoclonal antibodies targeting EGFR are often used in tumor targeted therapy. In addition, because EGFR is not expressed on the surface of T cells, when CAR-T cells are framed , the extracellular segment of EGFR can be co-expressed through the original T2A , which can indirectly reflect the expression of CAR .

This product FITC targeted conjugated EGFR monoclonal antibody of the extracellular domain (Cemab sequence ) , it can be used to EGFR overexpressing cell lines detected by flow cytometry and the CAR positive detection rate.


Product Name: EGFR Recombinant Antibody

Reactivity: human

Subclass: human IgG1

Purification method: affinity chromatography

Storage system: PBS, pH 7.4, 20% glycerol

Storage conditions: -20°C refrigerator, avoid repeated freezing and thawing


图片.png

Illustration: Lane M on the left is the protein MW marker, Lane 1 is the 4ug EGFR antibody;

The picture on the right shows the FACS detection of the binding of EGFR antibody to over-expressed EGFR CART.



Reference materials:

1. EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization

2. Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy
3. Potential relationship between normalization of endometrial epidermal growth factor profile and restoration of fertility in repeat breeder cows